Evogene (EVGN) Equity Average (2017 - 2025)
Evogene (EVGN) has disclosed Equity Average for 9 consecutive years, with -$766500.0 as the latest value for Q4 2025.
- Quarterly Equity Average fell 114.46% to -$766500.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$766500.0 through Dec 2025, down 114.46% year-over-year, with the annual reading at -$766500.0 for FY2025, 114.46% down from the prior year.
- Equity Average hit -$766500.0 in Q4 2025 for Evogene, down from $5.3 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $40.8 million in Q4 2022 to a low of -$766500.0 in Q4 2025.
- Historically, Equity Average has averaged $19.5 million across 5 years, with a median of $20.0 million in 2023.
- Biggest five-year swings in Equity Average: soared 208.42% in 2021 and later crashed 114.46% in 2025.
- Year by year, Equity Average stood at $32.2 million in 2021, then rose by 26.5% to $40.8 million in 2022, then plummeted by 50.99% to $20.0 million in 2023, then plummeted by 73.48% to $5.3 million in 2024, then crashed by 114.46% to -$766500.0 in 2025.
- Business Quant data shows Equity Average for EVGN at -$766500.0 in Q4 2025, $5.3 million in Q4 2024, and $20.0 million in Q4 2023.